Related Experiment Videos
Antivirals in the transplant setting.
1Centre for Virology, Department of Infection, Royal Free and University College Medical School, Rowland Hill Street, London NW3 2PF, United Kingdom. p.griffiths@medsch.ucl.ac.uk
Antiviral Research
|June 24, 2006
Summary
Antiviral drugs are now standard for preventing viral diseases in transplant patients, significantly reducing complications like graft rejection. This advancement has expanded transplantation, saving more lives.
Area of Science:
- * Transplantation medicine
- * Virology
- * Pharmacology
Background:
- * Antiviral drug use in transplant patients has evolved from experimental to routine over 25 years.
- * Viruses are implicated in major transplant complications, including graft rejection.
- * Effective antiviral therapies are crucial for managing post-transplant health.
Purpose of the Study:
- * To summarize key viruses impacting transplant recipients.
- * To review the evidence for antiviral drug use in preventing viral diseases post-transplantation.
- * To highlight the role of antivirals in facilitating clinical transplantation expansion.
Main Methods:
- * Review of randomized controlled clinical trials.
- * Analysis of the impact of antiviral drugs on transplantation outcomes.
- * Summary of viral pathogens relevant to transplant recipients.
Main Results:
- * Antiviral drugs have become integral to transplant care.
- * Significant reduction in transplant complications, such as graft rejection, attributed to antivirals.
- * Facilitation of broader clinical application of transplantation procedures.
Conclusions:
- * Antiviral drug development has revolutionized transplant medicine.
- * Routine use of antivirals improves patient outcomes and expands transplantation eligibility.
- * Evidence-based deployment of antiviral therapies is essential for preventing viral diseases in transplant patients.